Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 31 January 1969:
Vol. 163. no. 3866, p. 476
DOI: 10.1126/science.163.3866.476
Prev | Table of Contents | Next

Articles

Immunosuppressive Activity of Concanavalin A

Harold Markowitz 1, Donald A. Person 1, Gary L. Gitnick 1, and Roy E. Ritts Jr. 1

1 Section of Microbiology, Mayo Clinic and Mayo Foundation, and Mayo Graduate School of Medicine, University of Minnesota, Rochester

Two strains of mice (C-57 B] and DBA) were given skin allografts from Swiss ICR/HA mice and were treated with varying doses of concanavalin A; the dosage ranged from only two injections of 25 micrograms during the experiment to daily doses of 1000 micrograms intraperitoneally. Immullosuppression was present at all dosages, the most prolonged and consistent effect being observed at 300 micrograms per day. Grafts survived for 14 to 21 days at this dosage compared to 4 to 9 days for controls.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
{alpha}-Galactosylceramide-Induced Liver Injury in Mice Is Mediated by TNF-{alpha} but Independent of Kupffer Cells.
M. Biburger and G. Tiegs (2005)
J. Immunol. 175, 1540-1550
   Abstract »    Full Text »    PDF »
Ihibition of Cytotoxicity of Lymphocytes by Concanavalin A in vitro.
P. Perlmann, H. Nilsson, and M. A. Leon (1970)
Science 168, 1112-1115
   Abstract »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)